A study published in American Health Drug Benefits suggested that blood and stool-based screening tests could prompt more people to get screened for colorectal cancer.
Researchers created a model to examine the three-year clinical and economic impacts of Epigenomics AG's Epi proColon, fecal immunochemical testing and Exact Sciences' Cologuard. Epi proColon is a blood-based CRC screening test. Cologuard is a multitarget stool and DNA-based screening test. Researchers used the model to "screen" 34,800 of 81,200 unscreened individuals in a theoretical commercial health plan population.
Researchers said the model showed that the tests helped detect CRC earlier and at curable stages at a similar cost for patients who didn't want to undergo colonoscopy.
Read the entire study here.
Note: The study was funded by Epigenomics AG, of which two study authors serve as consultants to and one author serves as an employee.